"Study Title","Study Abbreviation","Authors","Published in","Date Published","Number of Randomized Patients","Conclusion","Primary Outcome","Results for the Primary Outcome","Blinding","Comparator","Link to Article"
"
  
    
    
    
    
      
  Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial


    
  
","NA","Vrselja, Amanda et al.","Lancet","2022/11/11","131","Q-122 is an effective and well tolerated non-hormonal oral treatment for vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.","Difference in the mean percentage change from baseline in the Vasomotor Symptom Severity Score of moderate and severe hot flushes and night sweats (msVMS-SS) between Q-122 and placebo after 28 days of treatment","Q-122 -39% [95% CI -46 to -31] vs placebo -26% [-33 to -18]; p=0*018).","Double-blind","Q-122 and placebo","https://pubmed.ncbi.nlm.nih.gov/36366886/?format=pubmed",
